Cite
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
MLA
Wang, Yang, et al. “Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.” Human Gene Therapy, vol. 30, no. 5, May 2019, pp. 651–60. EBSCOhost, https://doi.org/10.1089/hum.2018.170.
APA
Wang, Y., Zhou, X., Wu, Z., Hu, H., Jin, J., Hu, Y., Dong, Y., Zou, J., Mao, Z., Shi, X., Huo, Y., Lyu, J., Fang, Z., Zhang, W., Zhu, Y., Li, B., & Liu, B. (2019). Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2. Human Gene Therapy, 30(5), 651–660. https://doi.org/10.1089/hum.2018.170
Chicago
Wang, Yang, Xiaobing Zhou, Zhen Wu, Han Hu, Jing Jin, Yanping Hu, Yuting Dong, et al. 2019. “Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.” Human Gene Therapy 30 (5): 651–60. doi:10.1089/hum.2018.170.